Vlad and PR14 Sep 2025 16:18
Dr Vlad should seriously consider doing podcast and media interviews in the same way Tim McCarthy has at ImmuPharma, because the benefits are tangible. Tim’s openness and frequent outreach—including PR interviews and scientific updates—have boosted ImmuPharma’s visibility, helping drive investor interest. For instance, ImmuPharma’s shares more than quintupled over one recent month (from ~1.21p up to ~ 15.00p) as the market reacted to breakthrough findings in its P140 autoimmune research programme.  This kind of share‑price appreciation shows how powerful clear, consistent public communication can be: it builds momentum, improves investor sentiment, attracts new capital, and enhances credibility. If HEMO’s CEO follows a similar path, there’s a good chance it would help raise awareness, strengthen trust, and unlock value in the stock.